ICD-10-PCS Billable Code

CW7YYZZ

Systemic Nuclear Medicine Therapy Anatomical Regions, Multiple to None with None, Other Radionuclide Approach

Procedural Specifications

Clinical Axis Detail Definition
SectionC Nuclear Medicine
Body SystemW Anatomical Regions
Operation7 Systemic Nuclear Medicine Therapy
Body PartY Anatomical Regions, Multiple
ApproachY Other Radionuclide
DeviceZ None
QualifierZ None

Operation Definition

Introduction of unsealed radioactive materials into the body for treatment

Procedure Overview

Systemic nuclear medicine therapy involves giving unsealed, or free-flowing, radioactive material into the body, typically by injection or swallowing a capsule, so that it travels through the bloodstream and concentrates in a specific tissue to deliver a therapeutic dose of radiation from within. Radioactive iodine used to treat an overactive thyroid or thyroid cancer is the most familiar example, but the same principle applies to newer radiopharmaceuticals used to treat certain prostate cancers, neuroendocrine tumors, or bone metastases.

Because the material is unsealed rather than contained in a shielded implant, it distributes through the body based on the biological behavior of the carrier molecule, concentrating where that molecule is naturally taken up. This lets clinicians target diseased tissue with radiation while limiting the dose delivered to unrelated organs, and it is generally given in a monitored setting because of the systemic radiation exposure involved.

Anatomy & Axis Detail

Anatomical Regions, Multiple

The multiple anatomical regions value for systemic nuclear medicine therapy applies when treatment intent is directed at more than one distinct, identifiable region rather than the entire body diffusely, such as a patient receiving peptide receptor radionuclide therapy for neuroendocrine disease with separately documented target sites in both the abdomen and chest. This differs from the whole body designation in that the disease is not considered disseminated throughout the body but rather present at several discrete, named locations that the treating physician specifies. The distinction matters for accurate coding because it reflects a more limited, targeted disease distribution than a truly whole-body process, even though the radiopharmaceutical itself is delivered systemically. Documentation should list each anatomical region being treated so the encounter is coded to reflect the actual extent of targeted disease.

Radionuclide: Other Radionuclide

Other Radionuclide is used when a nuclear medicine study employs a radioactive tracer that does not correspond to one of the specifically named isotope values in this axis, such as an uncommon or newer radiopharmaceutical. It functions as a catch-all so the procedure can still be coded precisely by section and root operation even when the exact tracer lacks its own dedicated code value.

Coding & Documentation

Documentation supporting a code here should confirm that the radioactive agent given was unsealed, meaning it was administered as a liquid, capsule, or infusion rather than a sealed source, and should name or describe the radiopharmaceutical used, since that determines the qualifier. The clinical indication, such as thyroid ablation or treatment of a hormone-producing tumor, helps confirm the therapeutic rather than diagnostic intent of the administration.

A frequent coding error is confusing a diagnostic tracer dose, which is coded to imaging or probe families, with a therapeutic dose of the same isotope, which belongs here; the intent and dose level documented by the physician distinguish the two. Coders should also avoid defaulting to a generic radioactive substance qualifier when the specific agent is identified in the record.

Commonly Confused With

This family is most often confused with Brachytherapy, since both deliver therapeutic radiation using radioactive material. The key difference is that brachytherapy uses a sealed source placed at or near a specific site, while systemic therapy uses an unsealed substance that travels throughout the body via the bloodstream or gastrointestinal tract. It can also be confused with the diagnostic nuclear medicine families, such as PET Imaging or Nonimaging Probe studies, which use similar radioactive agents but at tracer doses intended to gather information rather than to treat disease.